Confronto

DSIP vs. Glepaglutide

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

62568-57-4

nessun dato

Peso molecolare

848.81 g/mol

nessun dato

Emivita

0.1 h

nessun dato

Sequenza

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

nessun dato

Meccanismo d'azione

DSIP

DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Base di evidenze

Evidenza più alta

Studio sull'uomo

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	DSIP	Glepaglutide
Germania	Non approvato	Non approvato
RU	Solo ricerca	—
Stati Uniti	Non approvato	Non approvato

Voci complete

Frequently asked questions

What is the difference between DSIP and Glepaglutide?: DSIP is classified as "Ricerca (altro)", while Glepaglutide is classified as "Ricerca (altro)". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, DSIP or Glepaglutide?: The highest available evidence level is "Studio sull'uomo" for DSIP and "RCT sull'uomo" for Glepaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of DSIP and Glepaglutide in Germany and the United States?: Germania: DSIP — Non approvato, Glepaglutide — Non approvato. Stati Uniti: DSIP — Non approvato, Glepaglutide — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

DSIP

Glepaglutide

Germania

Non approvato

Solo ricerca

—

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between DSIP and Glepaglutide?

DSIP is classified as "Ricerca (altro)", while Glepaglutide is classified as "Ricerca (altro)". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, DSIP or Glepaglutide?

The highest available evidence level is "Studio sull'uomo" for DSIP and "RCT sull'uomo" for Glepaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of DSIP and Glepaglutide in Germany and the United States?

Germania: DSIP — Non approvato, Glepaglutide — Non approvato. Stati Uniti: DSIP — Non approvato, Glepaglutide — Non approvato. These are factual summaries with source and review date on the individual pages.